Experimental drug aims to revive failing cancer fighters in rare sarcomas
NCT ID NCT07261657
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests an immunotherapy drug called N-803 in up to 8 people with synovial sarcoma or myxoid/round cell liposarcoma whose cancer got worse after a prior cell therapy. N-803 is designed to boost the patient's own immune cells that survived the earlier treatment, helping them attack the cancer more effectively. The main goals are to see if the drug is safe and whether it can expand those rare immune cells.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYXOID LIPOSARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Northwestern University
RECRUITINGChicago, Illinois, 60611, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a genetic marker guide future cancer therapies in taiwan?
- New immunotherapy targets rare cancers by harnessing the Body's immune system
- Experimental drug tazemetostat offered to patients with rare, aggressive tumors
- New pill may keep soft tissue sarcoma in check after chemo
- New registry aims to unlock secrets of rare sarcoma
- Glow-in-the-Dark dye could help surgeons find hidden lung cancer in teens